U.S. pharmaceutical giant lashes out at B.C. Ministry of Health after drug rejection
“It was not a complete evaluation of the trial, it was not a complete assessment of the clinical program for bamlanivimab, and no contact was made with Lilly seeking additional information prior to its publication.” Bamlanivimab is an antibody drug developed using technology from AbCellera Biologics that allows hundreds of thousands of tests to occur simultaneously to identify a virus protein, in this case COVID-19. The drug was approved for use in the U.S. and Canada last November, and since then Eli Lilly has shipped over 17,000 doses to other parts of Canada. No shipments have been ...